The Clinical Application of Immunohistochemical Expression of Notch4 Protein in Patients with Colon Adenocarcinoma

Int J Mol Sci. 2023 Apr 19;24(8):7502. doi: 10.3390/ijms24087502.

Abstract

The Notch signalling pathway is one of the most conserved and well-characterised pathways involved in cell fate decisions and the development of many diseases, including cancer. Among them, it is worth noting the Notch4 receptor and its clinical application, which may have prognostic value in patients with colon adenocarcinoma. The study was performed on 129 colon adenocarcinomas. Immunohistochemical and fluorescence expression of Notch4 was performed using the Notch4 antibody. The associations between the IHC expression of Notch4 and clinical parameters were analysed using the Chi2 test or Chi2Yatesa test. The Kaplan-Meier analysis and the log-rank test were used to verify the relationship between the intensity of Notch4 expression and the 5-year survival rate of patients. Intracellular localisation of Notch4 was detected by the use of the immunogold labelling method and TEM. 101 (78.29%) samples had strong Notch4 protein expression, and 28 (21.71%) samples were characterised by low expression. The high expression of Notch4 was clearly correlated with the histological grade of the tumour (p < 0.001), PCNA immunohistochemical expression (p < 0.001), depth of invasion (p < 0.001) and angioinvasion (p < 0.001). We can conclude that high expression of Notch4 is correlated with poor prognosis of colon adenocarcinoma patients (log-rank, p < 0.001).

Keywords: 5-year survival rate; Notch4; colon adenocarcinoma; immunogold labelling; immunohistochemistry (IHC).

MeSH terms

  • Adenocarcinoma* / pathology
  • Colonic Neoplasms* / pathology
  • Humans
  • Immunohistochemistry
  • Receptor, Notch4 / metabolism
  • Receptors, Notch
  • Signal Transduction

Substances

  • Receptor, Notch4
  • Receptors, Notch
  • NOTCH4 protein, human

Grants and funding

This research was funded by a grant from the Medical University of Silesia (no. PCN-1-181/N/1/I).